Subclinical Hypothyroidism and Thyroid Autoimmunity in Pregnancy: To Treat or Not to Treat
-
Maraka, Spyridoula [2] ; Dosiou, Chrysoula [1]
-
[1] Stanford University
Stanford University
Estados Unidos
-
[2] Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, University of Askansas for Medical Sciences, 4301 West Markham Street, Slot 587, Little Rock, AR 72205, USA; b Section of Endocrinology, Medicine Service, Central Arkansas Veterans Healthcare System, Little Rock, AR, USA; c Division of Endocrinology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA, USA
-
- Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 53, Nº. 2, 2024, págs. 363-376
- Idioma: inglés
- Enlaces
-
Resumen
Subclinical hypothyroidism and thyroid autoimmunity in pregnancy are common conditions. They are both associated with adverse maternal and offspring outcomes. Women with thyroid autoimmunity should be monitored with regular thyroid function tests preconception and during gestation to identify women who develop hypothyroidism. The effectiveness of thyroid hormone treatment in reducing adverse outcomes in pregnancy has been studied in a number of randomized controlled trials. Current evidence shows obstetrical benefits of levothyroxine treatment in pregnant women with a thyroid-stimulating hormone level greater than 4 mU/L
